Austin Aerts Sells 8,092 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 8,092 shares of the business’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $75,822.04. Following the transaction, the chief financial officer now owns 322,488 shares of the company’s stock, valued at $3,021,712.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Austin Aerts also recently made the following trade(s):

• On Tuesday, February 6th, Austin Aerts sold 9,786 shares of Sera Prognostics stock. The stock was sold at an average price of $8.03, for a total value of $78,581.58.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $9.46 on Thursday. Sera Prognostics, Inc. has a 1 year low of $1.52 and a 1 year high of $10.44. The business has a 50-day moving average of $8.40 and a 200-day moving average of $5.00.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Sera Prognostics by 9.1% in the 1st quarter. BlackRock Inc. now owns 47,870 shares of the company’s stock valued at $183,000 after purchasing an additional 3,974 shares during the period. Northern Trust Corp lifted its stake in Sera Prognostics by 20.8% in the 4th quarter. Northern Trust Corp now owns 32,842 shares of the company’s stock valued at $196,000 after acquiring an additional 5,651 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Sera Prognostics in the 1st quarter valued at approximately $39,000. StepStone Group LP bought a new stake in Sera Prognostics in the 4th quarter valued at approximately $61,000. Finally, Goldman Sachs Group Inc. bought a new stake in Sera Prognostics in the 1st quarter valued at approximately $41,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.